Company intelligence / Profile preview
Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd.
Shanghai, Shanghai, Chinaampsource.cn ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
The company has multiple programs in clinical development, with its lead candidate Recombinant FGF21-Fc fusion Protein (AP025) in Phase 2 for NASH. AP026 (FGF21/GLP-1 bifunctional protein) is in Phase 1 for Type 2 Diabetes. AP017 is in Phase 1 for Hemophilia A. KL-A289 (targeting LAG3) is in development for Advanced Malignant Solid Neoplasm.
- Therapeutic areas
- OncologyEndocrinologyHematologyGastroenterologyCardiovascular
- Modalities
- Fusion proteinsMonoclonal antibodiesBispecific antibodiesBiological macromolecular drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sino Biopharmaceutical's subsidiary CP Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (exclusive license and transfer agreement for AP025 and AP026)
Beyond the preview
Go deeper on Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd..